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1. Introduction 
The last few decades have shown a great progress in the development of antiviral agents 
that were licensed for treatment of Human immunodeficiency virus (HIV), herpesviruses, 
hepatitis viruses and respiratory viruses. The majority of viral infections clear 
spontaneously and are not in need for specific medical therapy. However, antiviral 
chemotherapy is indicated in certain clinical situations including: 
Those associated with fatal acute infections: Rabies virus, Respiratory syncytial virus, 
Hemorrhagic fever viruses (Lassa virus, Yellow fever, Dengue fever, Rift valley fever virus, 
Ebola virus) and pregnancy viral hepatitis as Hepatitis E virus (HEV) is associated with 20% 
fatality in pregnant females. 
Human viral infections that cause persistent infections (table 1) Human viral infections 
associated with loss of work hours; Rhinoviruses, Influenza A virus and diarrhoea causing 
viruses (Calciviruses, Norwalk viruses and Astra viruses). 
 
Family Virus Disease or consequence 
Retroviridae Human immunodeficiency virus (HIV) AIDS
Human T-cell lymphotrophic virus 
(HTLV) 
Leukaemia
Flaviviridae Hepatitis C virus (HCV) Chronic hepatitis, hepatocellular 
carcinoma Hepadanaviridae Hepatitis B virus (HBV) 
 
Herpesviridae 
Herpes simplex virus 1&2 
(HSV-1) (HSV-2) 
Recurrent mucocutaneous 
infections, encephalitis 
Varicella zoster virus (VZV) Recurrent neurological lesions 
Cytomegalovirus (CMV) Retinitis, pneumonia, encephalitis 
Epstein-Barr virus(EBV) Lymphoproliferative disorders 
Papovaviridae Human Papillomavirus (HPV) Cervical carcinoma, warts 
Table 1. Common human viruses known to cause persistent infections  
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2. Targets for antiviral drugs 
There are a number of virus-specific processes within the virus replicative cycle or  inside a 
virus infected cell, that have proven to be attractive targets for chemotherapeutic 
intervention, i.e., virus adsorption and entry into the cells, reverse (RNA to DNA) 
transcription, viral DNA polymerization, and cellular enzymatic reactions that are 
associated with viral DNA and RNA synthesis and viral mRNA maturation (i.e., 
methylation) (De Clercq , 2001). As emphasized by Lorizate and Krausslich, (2011), viruses 
have to cross the host cell boundary at least twice during their replication, thus alterations of 
membrane lipid composition can block viral release and entry, and certain lipids act as 
fusion inhibitors, suggesting a potential as antiviral drugs (Lorizate and Krausslich, 
2011).Most DNA viruses replicate in the nucleus and use cellular enzymes, but many DNA 
viruses have one or more specific viral enzymes for viral DNA replication. These enzymes 
are potential targets for effective antiviral agents. On the other hand, most RNA viruses 
replicate in the cytoplasm; only positive sense RNA viruses utilize the host machinery 
exclusively. dsRNA and negative-sense RNA viruses need to encode some, if not all virus 
specific enzymes for genome replication. while retroviruses have specific reverse 
transcriptase enzymes. Antiviral agents are effective inhibitors of these virus specific 
enzymes.  
As viruses direct the cell machinery for effective viral replication, an effective antiviral agent 
must prevent completion of the viral growth cycle in the infected cell without being toxic to 
the surrounding normal cells (Desselberger, 1995). 
The proper choice of antiviral agent relies on the selectivity index (SI) that is calculated to be 
the ratio of cellular toxicity to antiviral potency in vitro (Snoeck et al., 2002) 
3. Definition and classification of antiviral agents 
Antiviral drugs are a group of medication used for treatment of viral infections. It was 
formerly defined as substances other than a virus or virus containing vaccine or specific 
antibody which can produce either a protective or therapeutic effect to the clear detectable 
advantage of the virus infected host (Swallow, 1977). 
Classification of antiviral agents is based on identification of a particular virus target for 
inhibition of a specific viral replication step. 
3.1. Inhibitors of viral attachment/entry 
Virus particles attach to the surface of host cells through an attachment site. Some viruses 
have specific attachment sites widely distributed all over the host cell membrane that 
recognize molecules on the surface of virus particle. This is followed by activation of an 
enzymatic activity that helps a change of the attachment site to allow entry of the virus into 
the cell. Different families of viruses have specific virus enzyme(s) whose action is to 
facilitate entry into the host cell. For example, the attachment site for myxoviruses is sialic 
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acid and the virus enzyme is neuraminidase. Sometimes two different viruses share the 
same attachment/entry site e.g. Coxsackie and adenovirus receptor (CAR), but the way the 
individual virus utilize CAR differs.  
Many viruses use heparan sulphate as an attachment site (Dunn and Spear, 1989). Other cell 
membrane surface proteins are used as receptors by different viruses: Cluster of 
differentiation molecules (e.g. CD4), members of immunoglobulin (Ig) superfamily, 
chemokine receptors (e.g. CXCR4), glycolipids, lipoproteins, transmembrane proteins (e.g. 
Claudins), scavenger proteins or tumor necrosis factor (TNF) superfamily proteins. 
Interactions between viral surface proteins and host cell plasma membrane molecules 
frequently result in conformational changes that increase the efficiency of virus endocytosis/ 
phagocytosis and virus-mediated pathogenicity. 
Antiviral drugs may act by blocking the attachment process for specific viruses. Entry of 
HIV involves fusion between the viral lipid envelope and host plasma membrane. Fusion 
inhibitors can prevent HIV direct attachment and entry: Enfuvirtide (T-20) was the first 
approved viral entry inhibitor (Kilby and Eron, 2003). It inhibits fusion of HIV to cell by 
acting as a peptidomimetic that binds to the HIV gp41 envelope protein and thus preventing 
its attachment to CD4+ T cells. A circulating, highly specific natural HIV-1 inhibitor, 
designated virus-inhibitory peptide (VIRIP) was identified by Munch et al, (2007). VIRIP 
blocks HIV-1 entry by interacting with the gp41 fusion peptide and it was shown that a few 
amino acid changes increase its antiretroviral potency by two orders of magnitude. 
Maraviroc (UK-427,857) is a selective CCR5 cellular receptor antagonist with potent anti-
HIV-1 activity (Dorr et al, 2005, Lieberman-Blum et al, 2008). It serves to intercept viral-host 
protein-protein interactions mediating entry (Friedrich et al, 2011). 
St Vincent et al., (2010) showed that synthetic rigid amphipathic fusion inhibitors (RAFIs) 
inhibit the infectivity of several otherwise unrelated enveloped viruses, including hepatitis 
C virus (HCV) and HSV-1 and -2 with no cytotoxic or cytostatic effects (SI > 3,000) by 
inhibiting the increased negative curvature required for the initial stages of fusion. On the 
other hand, Wolf et al., (2010) reported LJ001 as a class of broad-spectrum antivirals effective 
against enveloped viruses that target the viral lipid membrane and compromises its ability 
to mediate virus-cell fusion. LJ001 specifically intercalated into viral membranes 
irreversibly, inactivated virions, while leaving functionally intact envelope proteins, and 
inhibited viral entry at a step after virus binding but before virus-cell fusion. Also, it was 
recently shown that the cellular Niemann-Pick C1-like 1 (NPC1L1) cholesterol uptake 
receptor is an HCV entry factor amendable to therapeutic intervention. Specifically, NPC1L1 
expression is necessary for HCV infection, as silencing or antibody-mediated blocking of 
NPC1L1 impairs cell culture-derived HCV (HCVcc) infection initiation (Sainz et al., 2012) 
The second step in viral replication cycle is penetration. Enveloped viruses penetrate by 
fusion of the viral membrane with the cell membrane (fusion from without); however, 
naked viruses penetrate the cell by phagocytosis of the virion from the extracellular fluid 
(fusion from within). Among antiviral agents that inhibit fusion are pooled 
immunoglobulin, hyperimmune serum & Enfuvirtide (T-20).  
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3.2. Inhibitors of virus uncoating and virus genome release 
In the cytoplasm cellular and virus proteases become activated by the acidic pH created 
inside the phagosome /endocytosome sac.Proteolytic digestion of virus capsid (naked 
viruses) or virus envelope (enveloped viruses) ends by complete release of virus genetic 
nucleoproteins. 
The viral genome is released and activated by several mechanisms specific to virus families. 
The details are much but the end result is the start of virus replication. 
Rimantadine and Amantadine specifically prevent uncoating of Influenza A (not B) virus. 
This is achieved by binding to virus  protein M2 and blocking its action as a proton ion 
channel that allows acidification of the virus core needed for activation of viral RNA 
transcriptase. In some strains, it may inhibit virus assembly. 
Amantadine is the 1-amino derivative of adamantine a complex 10- carbon compound with 
a cage-like structure and rimantadine is a nearly identical methyl derivative of amantadine 
(Hirsch et al, 1996). 
Characterization of the three-dimensional structure of picornaviruses in the 1980s allowed 
the development of compounds targeted at the virus itself (Florea et al, 2003). Pleconaril is 
known to be a broad spectrum anti-picornaviral agent that binds to a hydrophobic pocket in 
the viral capsid inducing conformational changes, which lead to altered receptor binding 
and viral uncoating (Romero, 2001). Pleconaril was designed to bind the highly conserved 
hydrophobic binding site on VP1 protein of Picorna viruses (Hussain Basha and Prasad, 
2012). Clinical studies have reported a reduction in the duration and intensity of symptoms 
in children and adults with enteroviral meningitis and in adults with rhinoviral respiratory 
tract infections treated with pleconaril. Also, pleconaril has demonstrated efficacy in the 
treatment of severe life-threatening enteroviral infections of the newborn and in 
immunosuppressed individuals. (Romero, 2001). 
3.3. Inhibitors of virus replication 
“All RNA viruses replicate in the cytoplasm except paramyxo viruses and retroviruses and 
all DNA viruses replicate in the nucleus solely except pox viruses.” 
RNA viruses with + ve RNA single strand genome that can act directly as virus mRNA e.g. 
polioviruses and hepatitis C virus use common “ cellular” machines for synthesis of virus 
protein termed internal ribosome entry site (IRES) – mediated translation. This system of 
translation initiation involves entry of 40 S ribosome internally to the 5⁄ untranslated region 
(UTR) of viral RNA by a cap- independent translation using specific virus initiation factors 
and IRES elements required for IRES mediated translation. Because there is no RNA 
polymerase proofing system, several mutations occur during new viral RNA genome 
formation leading to quasispecies of viral RNA genome. 
DNA viruses produce viral mRNA transcripts soon after the infection of a cell through host 
–cell enzyme, DNA dependent RNA polymerase II. DNA virus replication is semi 
 
Antiviral Replication Agents 131 
conservative and is very accurate since DNA polymerase checks the copied sequences 
(proofreading) and removes any mismatch. 
3.3.1. Polymerase inhibitors 
Acyclovir and other antiherpes nucleoside and nucleotide analog drugs; (Identified by the 
suffix –cyclovir/ -ciclovir"); Valacyclovir, Famciclovir, Penciclovir, Ganciclovir, Cidofovir 
(cytosine analogue). These agents interfere with virus replication and spread to new 
neighbouring cells by selective inhibition of an enzyme, thymidine kinase (TK) that the virus 
has but human cells do not, and thus interrupting the virus capability to synthesize its own 
DNA (table 2).CMV and EBV encode their own TK. HSV, VZV and EBV encoded TKs catalyze 
the phosphorylation of acyclovir to acyclovir monophosphate (ACVMP), as well as of 
thymidine and some other nucleoside analogue to their respective monophosphate. The 
markedly selective action of Acyclovir against HSV-1, HSV-2 and VZV is a consequence of 
several enzymatic reactions, each of which is unique for virus replication; 1) Specific activation 
by a virus induced TK into ACVMP, which is converted by cellular kinases to acyclovir di- and 
triphosphate (ACVTP), the metabolically active form of acyclovir. 2) Selective inhibition  of the 
viral DNA polymerase by ACVTP acting as a competitor with dGTP 3) termination of viral 
DNA chain elongation by incorporation of ACVMP (Hirsch et al, 1996)and 4) inactivation of 
the viral DNA polymerase following ACVMP incorporation in the presence of dNTPs 
(Reardon& Spector, 1992). Also, 2-chloro-3-pyridin-3-yl-5, 6, 7, 8-tetrahydroindolizine-1-
carboxamide (CMV423), showed very potent in vitro activity against human cytomegalovirus 
(HCMV). It acts on a step of the viral replicative cycle that precedes the DNA polymerase step 
and, most likely, coincides with the immediate early (IE) antigen synthesis (Snoeck et al, 
2002).It also acts against human herpes viruses (HHV) HHV-6, and HHV-7 at low 
concentrations, but shows only modest activity against herpes simplex virus (HSV) HSV-1 and 
-2 and none against varicella-zoster virus (VZV) (Snoeck et al., 2002; De Bolle, 2004). 
Telbivudine (LdT) is a synthetic thymidine nucleoside analogue. It is used to treat hepatitis 
B viral infection. It acts by blocking Viral DNA polymerase activity. Clinical trials 
demonstrated that telbivudine is safe and potent antiviral agent for treatment of chronic 
hepatitis B .It has superior efficacy compared to lamivudine( 3TC) and adefovir (Lui and 
Chan,2008) Systematic review and meta-analysis of clinical trials showed that LdT is 
superior in inhibiting HBV replication and preventing drug resistance as compared to 3TC 
for CHB patients (Zhao et al, 2010). Adefovir( ADV) (Leung, 2005), Tenofovir and Entecavir  
are also nucleoside analogues with anti-HBV activity. They competitively inhibit HBV DNA 
polymerase ending in viral DNA chain termination after replacing viral nucleosides. 
3.3.2. Nucleoside reverse transcriptase inhibitors (NRTIs) 
This group includes antiviral agents that are mainly recognized for the treatment of HIV, 
usually in combination with other retroviral drugs (Table 3). NRTIs are the first agents that 
were entered into clinical trials and received approval for treatment of HIV infection (Patick 
& Potts, 1998).  
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Drug Chemical structure Viruses Target 
Acyclovir Synthetic acyclic guanosine analogue 
[9(2hydroxyethoxymethyl)guanine] 
TK activated 
herpes simplex 
virus types 1 and 
2, varicella zoster 
virus (VZV) 
viral DNA 
polymerase 
Ganciclovir Nucleoside analogue (acyclic analogue of 
guanosine) that have an extra hydroxyl methyl 
group on the acyclic side chain. 
9-(1,3-dihydroxy- 2-propoxymethyl)guanine) 
virus UL97 gene-specified kinase activated 
(Mims et al, 2006) 
Herpes viruses 
especially CMV 
viral DNA 
polymerase 
Cidofovir Nucleotide analogue (S)-1-(3-
hydroxy2phosphonylmethoxypropyl)cytosine)
Not TK activated 
CMV, HSV, 
Adenovirus 
Papillomavirus 
viral DNA 
polymerase 
Vidarbine Nucleoside analogue (adenine) 
 (9-β-D-ribofuranosyladenine) 
Not TK activated 
HSV,VZV, (less 
effective against 
CMV & EBV), 
poxviruses, 
rhabdoviruses, 
hepadnaviruses  
viral DNA 
polymerase 
Idoxuridine Nucleoside analogue- iodinated thymidine. 
Replaces thymidine in the DNA -- blocks 
further elongation. 
Virus K activated 
 
Herpes viruses & 
other DNA 
viruses 
 
viral DNA 
polymerase 
Foscarnet Non nucleoside analogue (pyrophosphate 
analogue); phosphonoformic acid, trisodium 
salt. 
 Not TK activated 
cytomegalovirus 
(CMV) and 
herpes simplex 
viruses types 1 
and 2 (HSV-1 
and HSV-2 
viral DNA 
polymerase 
and HIV 
reverse 
transcriptase 
Table 2. Common viral DNA polymerase inhibitors 
Zidovudine  
Zidovudine (azidothymidine) is a synthetic pyrimidine analogue. It is an analogue of the 
nucleoside thymidine in which the hydroxyl group on the ribose is replaced by an azido 
group (Hirsch et al, 1996). After conversion to the triphosphate by cellular enzymes, it acts 
as a competitive inhibitor of, and substrate for the viral reverse transcriptase. The azido 
group prevents the formation of phosphodiester linkages. Proviral DNA formation is 
blocked because AZT triphosphate is incorporated into the DNA with resulting chain 
termination (Mims et al, 2006, Chapter 33). 
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Drug Chemical Name 
Target 
Viruses 
Zidovudine*(AZT; 
ZDV) 
Azidothymidine HIV 
Stavudine*(d4T) 2’,3’didehydro-3’-deoxythymidine HIV 
Zalcitabine*(ddC) 2’,3’- dideoxycytidine HIV 
Lamivudine*(3TC) dideoxy-thiacytidine analogue 
HIV 
Hepatitis B 
emtricitabine*(Emtriva) Deoxycytidine nucleoside analogue HIV 
Didanosine*(ddI) 2’,3’- dideoxyinosine HIV 
Abacavir (ABC) nucleoside analog reverse transcriptase inhibitor HIV 
Tenofovir**(Tenofovir 
DF) 
an acyclic nucleoside phosphonate (nucleotide) 
analog of adenosine 5'-monophosphate 
HIV 
* All are recognized by the "INE" suffix 
** Tenofovir is a nucleoTide reverse transcriptase inhibitor 
Table 3. Common Nucleoside Reverse Transcriptase Inhibitors 
Lamivudine (3TC)  
Lamivudine is a dideoxy-thiacytidine analogue with potent antiviral property against hepatitis 
B virus (Leung, 2005).Lamivudine acts as a nucleoside inhibitor of reverse transcriptase.It 
inhibits HBV reverse transcriptase, blocks the completion of the double stranded circular DNA 
before migration to the cell nucleus and prevents the infection of new hepatocytes. However, 
Lamivudine resistance developed after five years of monotherapy.  
Tenofovir (TDF) 
Tenofovir is a new nucleoside analogue with selective activity against hepatitis B virus. It 
was licensed in 2008 for the treatment of HBV infections in Europe and the United States 
(Schooley et al, 2002, Zhao et al, 2011). It is active against wild type and Lamivudine 
resistant HBV, both in vitro (Lada et al, 2004) and in vivo (Lacombe et al, 2005). 
Systematic review and meta-analysis of clinical trials was conducted by Zhao et al (2011) to 
compare the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B. Meta-
analysis indicated that a twelve-month TDF treatment was superior to ADV in inhibiting 
HBV replication in CHB patients. But there was no significant difference in the ALT 
normalization, HBeAg seroconversion and HBsAg loss rate.  
3.3.3. Non nucleosides reverse transcriptase inhibitors (NNRTI) 
Travertine, Delavirdine, Efavirenz, Nevirapine.  
These drugs directly bind to different sites in the reverse transcriptase (RT) enzyme and 
prevent its action. They do not require phosphorylation for activation and do not compete 
with nucleoside triphosphates. 
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3.3.4. Inhibitors of RNA synthesis (RNA polymerase inhibitors) 
Ribavirin: It is a synthetic purine nucleoside derivative- that resembles guanosine. Ribavirin 
inhibits guanosine triphosphate formation, prevents capping of viral mRNA, and blocks viral 
RNA-dependent RNA polymerase activity (Hirsch et al, 1996). It has got a broad spectrum 
antiviral activity as it inhibits replication of many DNA and RNA viruses such as HCV, 
Influenza A and B, parainfluenza, respiratory syncytial virus (RSV), paramyxovirus and HIV. 
The combination of Interferon alpha/Ribavirin therapy was approved by the United States 
regulatory authorities in 1998. The clinical efficacy of this combination exceeds that of the 
summation of individual monotherapies (Lau et al, 2002).Four mechanisms of action of 
ribavirin in HCV therapy were proposed. The first line of action consists of 2 possible 
indirect mechanisms: (1) enhancement of host T-cell–mediated immunity against viral 
infection through switching the T-cell phenotype from type 2 to type 1 and (2) inhibition of 
the host enzyme inosine monophosphate dehydrogenase (IMPDH). The second line of 
action consists of 2 other hypotheses: (1) direct inhibition of HCV RNA, including NS5B-
encoded RNA dependent RNA polymerase (RdRp) and (2) as an RNA mutagen that drives 
a rapidly mutating RNA virus over the threshold to “error catastrophe.” (Lau et al, 2002). 
On the other hand, specifically targeted antiviral therapy for hepatitis C (STAT-C) will 
probably supplement or replace present therapies. Leading compounds for STAT-C target 
the HCV nonstructural (NS) 5B polymerase and NS3 protease and helicase domain of the 
HCV NS3 protein (Belon and Frick, 2009).  
3.4. Inhibitors of viral protein synthesis 
All viruses use the cellular ribosomes to translate their viral mRNA. The later is translated 
into the structural proteins that will constitute core, envelope proteins and viral enzymes. 
As an example, the Enteroviruses (EV) RNA genome directs the synthesis of a single 
polyprotein that is autocatalytically processed into mature proteins at Gln↓ Gly cleavage 
sites by the 3C protease (3Cpro), which has narrow, conserved substrate specificity. These 
cleavages are essential for virus replication, making 3Cpro an excellent target for antivirus 
drug development (Costenaro et al, 2011). The crystal structure of 3Cpro from an 
enterovirus B, EV-93, a recently identified pathogen, alone and in complex with the anti-
HRV molecules compound 1 (AG7404) and rupintrivir (AG7088) was determined by 
Costenaro et al (2011). They found that the EV-93 3Cpro adopts a chymotrypsin-like fold 
with a canonically configured oxyanion hole and a substrate binding pocket similar to that 
of rhino-, coxsackie- and poliovirus 3C proteases (Costenaro et al, 2011). Collectively, 
neuraminidase enzyme regulates the synthesis of viral and cell membrane glycoprotein 
during Influenza virus A and B replication, which characterizes the enzyme as a target of 
viral protein modification inhibitors (neuraminidase inhibitors). 
Other examples of viral proteins synthesis inhibitors are Fomivirsen and Interferon. 
Fomivirsen is an oligonucleotide that binds to CMV mRNA and blocks its replication and 
thus inhibits the synthesis of proteins that are essential for production of infectious CMV. It 
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is a potent and selective antiviral agent for cytomegalovirus retinitis (Geary et al, 2002). 
Interferons are a group of virus induced proteins that interrupts new viral protein formation 
by several mechanisms .They possess direct complex intracellular antiviral, antiproliferative, 
and immunomodulating activities (Lau et al, 2002). IFN-α and -β have got antiviral activity 
whereas IFN-γ is predominantly immunomodulatory. rIFN-α and rIFN-β are approved for 
treatment of HCV, HBV, HPV and HHV-8 (Kaposi sarcoma) infections. 
Gene targeting studies have distinguished four main effector pathways of the IFN-mediated 
antiviral response: the Mx GTPase pathway, the 2', 5’-oligoadenylate-synthetase-directed 
ribonuclease L pathway, the protein kinase R pathway and the ISG15 ubiquitin-like 
pathway. These effectors pathways individually block viral transcription, degrade viral 
RNA, inhibit translation and modify protein function to control all steps of viral replication 
(Sadler &Williams, 2008). 
The aim of HCV/ HBV treatment is to develop a sustained decline of viral load by inhibition 
of viral replication, allowing CTL-derived cytokines to reduce the number of hepatocytes 
supporting viral replication by direct killing and also improvement of liver histopathology 
by the decline of HBV/HCV infected hepatocytes This will decrease fibrosis and hepatocytes 
regeneration with subsequent reduction of liver cirrhosis and thus prevention of 
progression to hepatocellular carcinoma.  
As suggested by Sainz et al, (2012), optimal HCV therapy will probably require a 
combination of antiviral targeting multiple aspects of the viral lifecycle. Recently, high rate 
of sustained virologic response was achieved when two direct-acting antiviral agents (NS5A 
replication complex inhibitor daclatasvir and the NS3 protease inhibitor asunaprevir) were 
combined with peginterferon alfa-2a and ribavirin for treatment of HCV chronic hepatitis 
patients (Lok et al, 2012). 
Several drugs are recommended for treatment of patients with chronic hepatitis B 
(CHB).These anti HBV drugs are used to compose combinational therapy with the addition 
of interferon sometimes to delay drug resistance. These drugs can be divided into two main 
groups based on their mechanism of action, namely immunomodulatory drugs like alpha 
interferons and antiviral drugs including lamivudine(LAM), telbivudine(LdT), 
entecavir(ETV), adefovir(ADV), and tenofovir(TDF) (Zhao et al, 2011).Interferon and 
Lamivudine have been the only approved agents for a while. The approval of Adefovir in 
2002, Pegylated Interferons and Entecavir in 2005 opens up more choices and chances 
(Leung, 2005). 
3.4.1. Protease inhibitors (PIs): (inhibit the post-translational events) 
Various drugs recognized by “NAVIR” suffix are known to have the same mode of action; 
Amprenavir, Saquinavir, Darunavir, Atazanavir, Ritonavir, Tipranavir Indinavir, Nelfinavir. 
This group of drugs acts by preventing the activity of cellular/viral proteases enzymes. 
Proteases are valid targets for antiviral agents as they are essential for the production of 
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mature infectious virus particles. Molecular studies have indicated that viral proteases play 
a critical role in the life cycle of many viruses by affecting the cleavage of high-molecular-
weight viral polyprotein precursors to yield functional products or by catalyzing the 
processing of the structural proteins necessary for assembly and morphogenesis of virus 
particles (Patick & Potts, 1998). 
Several studies elaborated the value of protease inhibitors for the treatment of a lot of RNA 
and DNA viruses; HIV, HCV, Picorna viruses, RSV, Herpes viruses, Rota virus & severe 
acute respiratory syndrome virus (SARS). HIV protease inhibitors have emerged as potent 
antiretroviral chemotherapeutic agents that, in combination with RTIs, have resulted in 
prolonged suppression of viral replication (Patick & Potts, 1998). Also, in HCV treatment, 
direct acting antivirals (DAA), in clinical development include NS3-4A protease inhibitors 
(two of which, telaprevir and boceprevir, have recently been approved for treatment of HCV 
genotype 1 infection in combination with pegylated interferon-α and ribavirin (Pawlotsky, 
2012). Replication of picornaviruses and coronaviruses requires 3Cpro (3C protease) and 
3CLpro (3C-like protease) respectively, which are structurally analogous (Ramajayam et al, 
2011). A group of common inhibitors against 3C (pro) and 3CL (pro) were found recently 
(Wang and Liang, 2010). 
3.4.2. Integrase inhibitor: Raltegravir 
Integrase is an essential HIV-1-specific enzyme that is an active target for antiretroviral drug 
development. The drug specifically inhibits strand transfer, one of the three steps of HIV 
integration into the host DNA (Katlama and Murphy, 2009) and thus prevents human 
immunodeficiency virus from multiplying in the host. 
Inhibition of HIV replication initially targeted viral enzymes, which are exclusively 
expressed by the virus and not present in the human cell (Sierra-Aragón and Walter, 2012). 
Table 4 illustrates Common FDA approved antiviral agents for the treatment of HIV 
infection (www.fda.gov/.../hivandaidsactivities/ucm118915.ht.) 
Analogue to HCV therapy, combination therapy for treatment of HIV reduces HIV 
replication with subsequent drop in viral load. Two NRTIs in combination with the NNRTI 
or PI drugs have had a dramatic effect on progression to AIDS and led to the term Highly 
Active Anti-Retroviral Therapy (HAART) (Mims et al, 2006- chapter 21). The combination 
includes: 
Nucleoside/ Nucleotides Reverse Transcriptase Inhibitors (NRTIs) such as Tenofovir and 
Abacavir 
Non-Nucleoside/ Nucleotides Reverse Transcriptase Inhibitors (NNRTIs) such as Efavirenz 
and Nevirapine 
Integrase Inhibitors such as Raltegravir 
Protease Inhibitors (PIs) such as Darunavir and Atazanavir 
Fusion and Entry Inhibitors such as Enfuvirtide and Maraviroc. 
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Name Mechanism of action 
Lamivudine,zidovudine,emtricitabine, 
abacavir, stavudine,didanosine, zalcitabine 
Nucleoside Reverse Transcriptase 
Inhibitors (NRTIs) 
tenofovir disoproxil fumarate Nucleotide reverse transcriptase inhibitor 
(NtRTI) 
Rilpivirine,delavirdine,etravirine,efavirenz, 
nevirapine,nevirapine 
Nonnucleoside Reverse Transcriptase 
Inhibitors (NNRTIs) 
Amprenavir, tipranavir, lopinavir (combined 
with ritonavir at a 4/1 
ratio),indinavir,ritonavir,darunavir, nelfinavir, 
atazanavir 
Protease Inhibitors (PIs) 
 
enfuvirtide, T-20 Fusion Inhibitors 
maraviroc Entry Inhibitors - CCR5 co-receptor 
antagonist 
raltegravir integrase inhibitors 
(www.fda.gov/.../hivandaidsactivities/ucm118915.ht.) 
Table 4. Common FDA approved antiviral agents for the treatment of HIV infection 
3.5. Inhibitors of viral exit (release) 
Viral release is done by single burst releasing millions of new viral particles from infected 
cells or by slow process of budding through the plasma membrane allowing the infected cell 
to survive for several days while supporting viral replication and release. In general, lytic 
viruses (e.g: polio) are released by lysis and death of the cell. Others (e.g. influenza, HIV, 
and measles) escape by budding from the cell surface. 
3.5.1. Neuraminidase inhibitors 
Oseltamivir and Zanamivir are antivirals used to treat and prevent influenza (Jefferson et al, 
2012). They Inhibit neuraminidases produced by influenza A and B (enzyme which cleaves 
the interaction between sialic acid cell surface receptors and viral proteins and surface 
proteins of infected cells and thus allow for release of virions) Therefore, these drugs 
interfere with the release of influenza virus from infected host cells. 
Table 5 sums up antivirals that are available commercially, used by physicians and 
approved by international and national regulatory authorities. 
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Virus Anti-Viral Drugs 
Human immunodeficiency virus 22 approved agents 
Hepatitis C virus pegIFN, Ribavirin 
Hepatitis B virus Interferon-alpha (pegylated), Lamivudine, adefovir 
Herpesviruses Acyclovir,famciclovir,valacyclovir,ganciclovir, 
cidofovir, formivirsen,valganciclovir 
Influenza Amantadine, rimantadine,zanamivir, oseltamivir 
Respiratory syncytial virus Ribavirin, Palivizumab 
Picornaviruses pleconaril 
Papillomaviruses IFN(intra-lesional), ?cidofovir, Fluorouracil 
Rhinoviruses Tremacamra (rsICAM-1) 
Table 5. Master Anti-Viral Drugs 
4. Antiviral from plants 
Plants and plants extracts have been used chiefly as traditional medicine for centuries even 
before the active principles in the plant products could be elucidated through the 
improvements in science and technology. The World Health Organisation (WHO) has 
estimated that perhaps 80% of the world’s population rely on traditional medicine for the 
treatment of infectious diseases (Abonyi et al, 2009). 
Several naturally occurring dietary flavonoids including quercetin, hesperetin, and catechin 
were previously studied in vitro in cell culture monolayers using viral plaque reduction 
technique and proved to be effective on the infectivity and replication of HSV-1, poliovirus 
type 1, parainfluenza virus type 3 (Pf-3), and respiratory syncytial virus (RSV). Quercetin 
caused a concentration-dependent reduction in the infectivity of each virus. Hesperetin had 
no effect on infectivity but it reduced intracellular replication of each of the viruses. 
Catechin inhibited the infectivity but not the replication of RSV and HSV-1 and had 
negligible effects on the other viruses (Kaul et al, 1985). 
We previously had the opportunity to evaluate extracts of five different herbal plants for 
hepatitis A (HAV) antiviral activities by plaque reduction assay. These plants were anise, 
chamomile, liquorice, nigella and thyme. A fast growing HAV-10 reported to be cytopathic 
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for Vero cell culture was used where the plant extracts were screened for anti-infective, 
protection and antireplicative activities. The rates of the anti-infection studies were arranged 
in a decreasing order as follows: anise> liquorice > chamomile > thyme>. The rates of the 
protective antiviral activities were found to be as follows: chamomile >liquorice> thyme > 
anise. The rate of the anti-replication effect was ordered in the following decreasing order: 
thyme > liquorice > chamomile > nigella. Thus anise extract was devoid of any anti-
replication activity, whereas nigella extract was devoid of any protective activity against 
HAV infection in vitro (Omran et al, 2001)            
Also, another Egyptian study evaluated the antiviral activities of the essential oils of the 
fresh leaves of 3 Melaleuca species; M. ericifolia, M. leucadendron, and M. armillaris against 
Herpes simplex virus type 1 (HSV-1) in African green monkey kidney cells (Vero) by a plaque 
reduction assay. It was found that the volatile oil of M. armillaris was more effective as a 
virucidal (up to 99%) than that of M. leucadendron (92%) and M. ericifolia (91.5%) (Farag et al, 
2004).  
Amylose extracted from Grateloupia filicina have antivirus activity in the stage of HSV-2 
binding, adsorption and ingression with Vero cell (Zhu et al, 2006). 
Also, it was shown by Verma et al, (2009) that Picroliv or Kutkin of Picrorhiza kurroa which 
constitute an important component of many Indian herbal preparations has anti-viral and 
immune-stimulant activities. 
Screening of the antiviral activity of oil extract of Balanites aegyptiaca (Balantiaceae) fruits 
against Herpes simplex virus type -1 in African green monkey kidney cells (Vero) by a 
plaque reduction assay, illustrated that the oil had virucidal activity (58.3%) against Herpes 
simplex virus type 1 at concentration 50μg/ml compared with acyclovir (60%) at the same 
concentration (Al Ashaal et al, 2010).  
The antiviral activity of Balanites aegyptiaca herb was also reported against HIV/AIDS 
(Chaudhry and Khoo, 2004). 
We also have the experience of testing extracts from Egyptian medical plants for their 
potential antiviral activity at different stages of viral replication. The anti-influenza activity 
of hydro-alcoholic extracts from; Cleome droserifolia, Justicia ghiesbreghtiana, and 
Thunbergia grandiflora against a fast growing Influenza "A" reference strain (H3N2) in 
replicating Madin–Darby Canine kidney (MDCK) was performed. Amantadine was used as 
reference anti-influenza virus drug. Three antiviral assays were used; Anti-infectivity, 
protective and anti-replication mechanisms, reduction in the number of plaques formed by 
the virus in MDCK cells treated with maximum non toxic dose (MNTD) of each plant 
extract was analyzed. Justicia extract showed the highest significant inhibition of influenza 
virus infectivity .On the other hand, when MDCK cells were pretreated with cleome extract 
for 48 hours before infection with influenza virus, it showed the highest significant anti-
influenza virus activity. Whereas, when cleome extract was added to MDCK infected with 
influenza virus after 60 min of infection, it induced significant inhibition in influenza virus 
type A replication in a dose dependent relation. Thunbergia extract had the least antiviral 
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activity. Phytochemical screening tests showed that all of the studied extracts contain 
tannins but flavonoids are present in the Cleome and Justicia extracts only. Two major 
compounds of cleome extract; Isorhamnetin-3-0-B glucopyranosyl-7-0 -L-rhamnopyranoside 
and quercetin -3-0-B – glucopyranosly-7-0-L rhamnopyranoside were studied for their 
antiviral activity by the three different assays. The results proved that isorhamnetin 
produced inhibition of influenza virus infectivity stronger than that produced by the total 
cleome extract (Elkosy et al, 2005). 
Antiviral activity of dandelion extracts against influenza viruses was reported by Wen et al, 
(2011). Mechanisms of reduction of viral growth in MDCK or A549 cells by dandelion 
involve inhibition of virus replication. Dandelion extracts inhibited infections in Madin-
Darby canine kidney (MDCK) cells or Human lung adenocarcinoma cell line (A549) of PR8 
or WSN viruses, as well as inhibited polymerase activity and reduced virus nucleoprotein 
(NP) RNA level. The plant extract did not exhibit any apparent negative effects on cell 
viability, metabolism or proliferation at the effective dose (Wen et al, 2011). 
In general, the medicinal plants are potential antiviral agents that are locally available, 
relatively cheap, can be tested for safety and non toxicity and culturally acceptable to the 
community. 
5. Conclusions 
Potent antiviral agents are on the increase leading to improved patient management. 
Viruses replicate inside live nucleated cells in different steps using cellular machinery, but 
sometimes virus specific enzymes are used. This allows for the selection of virus specific 
molecules as targets of antivirals. An effective antiviral therapy depends greatly on its 
ability to block viral entry or viral exit from infected cell or inhibiting active viral replication 
steps. Proper understanding of these steps at molecular level and the use of advanced in 
silico design for development of antivirals that specifically react with viral target molecule 
may provide new insight for their potential activity and prophylaxis against viral infections.  
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